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Abstract 
Background: The COVID‑19 pandemic reached Europe in early 2020. Convalescent plasma is used without a consist‑
ent evidence of efficacy. Our hypothesis is that passive immunization with plasma collected from patients having 
contracted COVID‑19 and developed specific neutralizing antibodies may alleviate symptoms and reduce mortal‑
ity in patients treated with mechanical ventilation for severe respiratory failure during the evolution of SARS‑CoV‑2 
pneumonia.
Methods: We plan to include 500 adult patients, hospitalized in 16 Belgian intensive care units between September 
2020 and 2022, diagnosed with SARS‑CoV‑2 pneumonia, under mechanical ventilation for less than 5 days and a 
clinical frailty scale less than 6. The study treatment will be compared to standard of care and allocated by randomiza‑
tion in a 1 to 1 ratio without blinding. The main endpoint will be mortality at day 28. We will perform an intention to 
treat analysis. The number of patients to include is based on an expected mortality rate at day 28 of 40 percent and an 
expected relative reduction with study intervention of 30 percent with α risk of 5 percent and β risk of 20 percent.
Discussion: This study will assess the efficacy of plasma in the population of mechanically ventilated patients. A 
stratification on the delay from mechanical ventilation and inclusion will allow to approach the optimal time use. 
Selecting convalescent plasmas with a high titer of neutralizing antibodies against SARS‑CoV‑2 will allow a homoge‑
neous study treatment. The inclusion in the study is based on the consent of the patient or his/her legal representa‑
tive, and the approval of the Investigational Review Board of the University hospital of Liège, Belgium. A data safety 
monitoring board (DSMB) has been implemented. Interim analyses have been planned at 100, 2002, 300 and 400 
inclusions in order to decide whether the trail should be discontinued prematurely for ethical issues. We plan to pub‑
lish our results in a peer‑reviewed journal and to present them at national and international conferences.
Funding and registration: The trial is funded by the Belgian Health Care Knowledge Center KCE # COV201004
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Strengths and limitations of this study
1 This study will be the first to assess the efficacy of 
plasma collected from convalescents of COVID-19 
in the population of mechanically ventilated patients. 
The high mortality of this specific population 
increases the chance to observe a difference between 
the two groups.
2 The prospective and randomized design will allow to 
give a solid answer to the question. A stratification 
on the delay from mechanical ventilation and inclu-
sion in the study will allow to determine the optimal 
time to use the convalescent plasma
3 The participation of 16 centers of all Belgium will 
insure the external validity of the results and the 
recruitment of the patients in an acceptable time 
period
4 Selecting convalescent plasmas with a high titer of 
neutralizing antibodies against SARS-CoV-2 will 
guaranty an homogeneous treatment in the interven-
tion group
5 Planning iterative interim analyses will allow to stop 
the trial early in case of an ethical issue induced by 
the observed results
Background
The COVID-19 pandemic started in China in December 
2019 and spread to European countries in early 2020, 
affecting most severely Italy, Spain and France. Belgium 
was affected during the same wave and first deaths due 
to COVID-19 were reported in early March 2020. As of 
October 2020, more than 30 million cases, including 1 
million deaths, have been confirmed over the world and 
almost 90,000 cases, including 9900 deaths, have been 
declared in Belgium [1]. The potential duration of the 
current pandemic is largely unknown and epidemics with 
coronaviruses are likely to recur.
Current data from the Belgian surveillance system indi-
cate that 20% of the hospitalized patients are in ICUs 
[2]. Thirty to sixty percent of the mechanically venti-
lated patients are likely to die [3, 4]. A race for develop-
ing active therapies and vaccines started since the onset 
of the pandemic [5]. Therapy with plasma collected from 
convalescent patients has been proposed to provide pas-
sive immunization to the patients at risk of developing 
severe COVD-19 in preliminary studies [6, 7] and in a 
randomized controlled trial that ended prematurely due 
to the end of the contaminations in China [8]. In this 
series, 103 patients were randomized and a subgroup 
analysis indicated that convalescent plasma was asso-
ciated with a 30% relative reduction of mortality in the 
severe patients [8]. A direct antiviral effect of neutral-
izing antibodies within the convalescent plasma is likely 
to play a central role in the beneficial effect of the treat-
ment. Two consecutive surveys in USA indicated that 
the use of convalescent plasma appears safe. Serious 
adverse events attributed to the plasma were estimated 
to be around 0.02 percent in 5,000 patients and mortal-
ity was estimated to be 41% at day 30 in those 27 percent 
of the patients who were under mechanical ventilation [9, 
10]. In this series, the titer of antibodies measured in the 
convalescent plasma was correlated to the survival of the 
patient [10]. In a series of 175 patients with mild COVID-
19 from Shangaï, China, Wu et al. [11] observed that the 
titers of neutralizing antibodies assessed at hospital dis-
charge to SARS-CoV-2 varied substantially. In 11 patients 
with sequential assessments, high titers over 1/256 were 
measured as early as 10 to 16 days of disease onset.
As of October 6, 2020, 71 randomized controlled tri-
als have been posted on Clinicaltrials.gov. Eighteen trials 
plan to enroll at least 300 patients. This study is the only 
one to include specifically mechanical ventilated patients.
Our hypothesis is that passive immunization with 
plasma collected from patients having contracted 
COVID-19 and developed specific antibodies may allevi-
ate symptoms and viral load of SARS-CoV-2 and reduce 
mortality in patients treated with mechanical ventila-
tion for severe respiratory failure during the evolution 
of SARS-CoV-2 pneumonia as compared with standard 
of care (SOC). Considering the high number of current 
trials testing therapies against COVID-19, we anticipate 




The principal objective of our trial is to assess the effi-
cacy of 2 units (400–500 mL) of plasma collected in con-
valescents of COVID-19 infection with a titer greater 
or equal to 1/320 neutralizing antibodies against SARS-
CoV-2 associated with SOC, as compared to SOC alone, 
to reduce the mortality at day 28 after inclusion of the 
Trial registration: Clinicaltrials.gov registration number NCT04558476. Registered 14 September 2020—Retrospec‑
tively registered, https ://clini caltr ials.gov/ct2/show/NCT04 55847 6
Keywords: COVID‑19, Convalescent plasma, Randomized, Respiratory failure, Mechanical ventilation
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patients with SARS-CoV-2 pneumonia who require 
mechanical ventilation.
The secondary objective is to assess the efficacy in 
terms of clinical outcomes, as assessed by.
1 day-90 mortality
2 duration of mechanical ventilation
3 severity of organ failure
4 use of organ support
5 viral load of the airway
6 inflammatory response
7 hospital length of stay
8 functional, psychological state and quality of life
9 adverse events related to plasma transfusion and to 
organ support
Trial design and participants
This is a multicenter two-arm open label randomized 
superiority trial, with a stratification based on the delay 
from tracheal intubation to inclusion. The trial will be 
conducted in the intensive care units (ICUs) of the par-
ticipating centers in accordance with consensus ethi-
cal principles derived from the Declaration of Helsinki, 
as well as the quality standards of Good Clinical Prac-
tice. The participating centers are listed at https ://clini 
caltr ials.gov/ct2/show/NCT04 55847 6. They have been 
selected according to a feasibility survey, if they had 
admitted at least 20 patients fulfilling the inclusion cri-
teria during the March–April 2020 period. This trial has 
been registered at clinicaltrials.gov as NCT04558476. It 
has been approved by the Central Ethics Committee of 
the University hospital of Liège, Belgium on September 
1, 2020, number # 2020/239. The study is expected to last 
from September 2020 to September 2022. Each patient 
will be followed-up for 365 days after enrolment.
Patient and public involvement
No patient involvement.
Recruitment and selection of convalescent donors
Convalescent plasma donors will be recruited by the 
Belgian Red-Cross in a population of patients that were 
infected with SARS-CoV-2 and recovered, according to 
national legal requirements to donate blood or plasma. 
Donors will be adults, asymptomatic with prior diag-
nosis of COVID-19, at least 28  days will having passed 
since full recovery. They must not have a history of blood 
transfusion or tissue or organ transplantation, positive 
screening for irregular antibodies. Female donors can 
only be recruited if no history of pregnancy or tested a 
negative for anti-HLA/HPA/HNA antibodies. Standard 
donor criteria for blood or plasma donation must be met 
and informed consent must be obtained in accordance 
with the Belgian Blood Legislation and national and EU 
data protection rules.
Plasma collection from the selected donors
Collection, processing and storage.
The plasma collection will be performed in a dedicated 
facility, by plasmapheresis, or if apheresis is not sufficient 
to supply enough plasma, by plasma separation of the 
whole blood. Eligible plasmapheresis donors are allowed 
to donate a total volume per year of 650 ml per session, 2 
L per month and 15 L per year. The inter-donation inter-
val is at least one week. Plasma obtained by plasmapher-
esis and processed will be split before freezing into 2–3 
separate units (e.g. 3 × 200  ml). Final products will be 
specifically labelled as COVID-19 Convalescent Plasma 
and stored in a dedicated location. The processing that 
is routinely used for pathogen reduction by Methylene 
Blue will be applied according to standard practice in 
the blood establishment. The product can be stored for 
36 months at a temperature below- 25 °C or for 3 months 
at a temperature between -18 °C and -25 °C. The date of 
the positive diagnosis of COVID-19 and the time from 
diagnosis until resolution of symptoms will be collected 
from the donors.
Assessment of the neutralizing antibodies in the donated 
plasma
A serum sample from all donors will be stored for test-
ing of antibody specificities. The blood service of the 
Belgian Red-Cross will determine SARS-CoV-2 neutral-
izing antibody titers to select donors with high titers. The 
neutralizing antibody titers will be repeated with a maxi-
mal interval of one month. Samples of donations done 
in-between will be stored for later testing. The blood ser-
vice of the Belgian Red-Cross will qualify donations from 
donors with neutralizing antibody titers greater or equal 
to 1/320 as appropriate for this study. In case of short-
age of plasma with a titer greater or equal to 1/320 on 
the moment of patient enrolment, plasma from convales-
cent donors with a titer of at least 1/80 will be released 
for transfusion. Virus neutralization test (VNT) is car-
ried out with SARS-CoV-2 strain BetaCov/Belgium/Sart-
Tilman/2020/1 in 96-well plates containing confluent 
Vero E6 cells (ATCC CRL-1586) [12]. We use 8 dilutions 
of each heat inactivated serum (1:10 to 1:1280—corre-
sponding to final testing dilutions 1:20 to 1:2560), allow-
ing testing 2 samples or controls per plate. In each VNT, 
a strong, assured positive control serum from Belgian 
National Reference Centre (Sciensano) is used. Sera are 
mixed vol/vol with 100 TCID50/reaction of SARS-CoV-2 
and incubated 1  h at 37  °C. Then, the serum plus virus 
mixture is transferred onto the confluent cell monolayer 
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in triplicate. The VNT relies on cytopathic effect (CPE) 
observation under light microscopy at day 5 pi. Dilutions 
of serum associated with CPE is considered as negative, 
while the absence of CPE indicated a complete neutrali-
zation of SARS-CoV-2 inoculum (positive). Virus neu-
tralization titer is reported as the highest dilution of 
serum that neutralized CPE in 50% of the wells. Serum 
specimens with a titer ≥ 40 are considered to neutralize 
the virus.
Study intervention and procedures
The patients hospitalized with a severe COVID-19 infec-
tion will be proposed to participate if they fulfill the fol-
lowing criteria:
 (1) age at least 18 years
 (2) hospitalization in an intensive care unit partici-
pating to the study
 (3) medical diagnosis with SARS-CoV-2 pneumonia 
as defined by both:
(a) extended interstitial pneumonia on CT scan or 
a chest X-ray, consistent with viral pneumonia, 
within 10 days prior to inclusion
(b) Positive result of SARS-CoV-2 PCR test, or 
any emerging and validated diagnostic labora-
tory test for COVID-19, within 15 days prior to 
inclusion
 (4) under mechanical ventilation administered 
through an endotracheal tube, for less than 
5 days
 (5) Clinical Frailty Scale < 6 before hospitalization 
[13]
 (6) informed consent of the patient, or—if impossi-
ble—of a relative acting as the legal representa-
tive, or—if impossible—of a physician from a 
non-participating department of the same hospi-
tal acting as an impartial witness.
 (7) absence of pregnancy
 (8) absence of prior episode of transfusion-related 
side effect
 (9) absence of medical decision to limit therapy
 (10) absence of current participation in another trial 
testing a COVID-19 therapy
Participant or legal representative consent, inclusion 
and randomization process
Prior to request consent from the patient, the investi-
gator will contact the study coordinating center (UCL 
clinical trial center, Pr Laterre), which will check both the 
inclusion criteria and the availability of the convalescent 
plasma of the ABO blood type of the eligible patient on 
the website of the Belgian Red-Cross. Then, the capabil-
ity to be informed and to provide their consent will be 
assessed for all potential patients. If the written consent 
of the patient cannot be obtained, it will be asked from 
a relative/legal representative of the patient or from an 
impartial witness. The witness can be a physician from 
another department of the hospital. The eligible patients 
will be unable to speak—due to tracheal intubation—and 
most often likely not able to understand the information 
about the benefits and risks of the trial—due to seda-
tion and/or confusion due to COVID-induced sepsis. 
Their relatives will likely be only contacted by phone and 
asked to send a written consent by email, according to 
the guidelines of the participating ICU, which most fre-
quently preclude access of visitors to the hospitals due to 
the pandemic aspect of COVID-19. In case of inclusion 
without the written consent of the patient and in case of 
recovery, his/her consent to continue to participate and/
or to use his/her personal data will be requested. The 
process of randomization will be performed through a 
standard randomization system (UCL clinical trial center, 
Pr Laterre) either directly through the eCRF system or 
by the CCC St Luc. The randomization process will be 
stratified according to the delay from tracheal intubation 
to inclusion (“<= 48 h”; “between 48 h and 5 days”). A 
response to telephone calls for any issue regarding the 
inclusion criteria will be available 24/7. The treatment 
(intervention versus control) will be allocated in 2 arms 
in a 1:1 ratio.
Study arms
We used blocked randomization to form the allocation 
list for the two comparison groups. We used a computer 
random number generator, R software, to select random 
permuted blocks with a block size of four and an equal 
allocation ratio. The randomization process was stratified 
according to the delay from tracheal intubation to inclu-
sion (<= 48 h and between 48 h and 5 days).
When the patient is randomized in the intervention 
arm, he/she will be administered 2 units (400–500  mL 
in total) of convalescent plasma. The units of plasma will 
be shipped by the Belgian Red-Cross to the local blood 
bank. The treatment will be administered within 24  h 
of inclusion in the study and within six hour after thaw-
ing, through a venous line over at least 2 h. The patients 
randomized to control arm will not receive convalescent 
plasma. No cross-over will be allowed between the two 
arms. The two groups will be treated with the current 
SOC, made of therapies currently recommended in inter-
national guidelines regarding organ failure support and 
treatment of secondary events and treatment directed 
against SARS-CoV-2 or the inflammatory response 
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to the infection. At the present time, this treatment 
includes steroids, in accordance with the recently pub-
lished “Recovery” trial [14]. In case of evolution of the 
guidelines due to new scientific release during the study 
period, the SOC will be adapted in the two treatment 
groups.
Evaluation visits
Patients will be evaluated during the screening period 
for inclusion criteria, on day 1 for the inclusion visit, on 
days 7, 14 21 28, 90 and 365 for follow-up visits and every 
day in the ICU to assess the occurrence and duration of 
organ supportive techniques and secondary events. In 
case of discharge of the hospital, the visits will be per-
formed either by phone or visual contact. The Table  1 
illustrates the schedule of assessments at each phase of 
the follow-up.
Data sharing
The data will be shared at the European level in accord-
ance with Belgian and KCE requirements https ://
ec.europ a.eu/healt h/blood _tissu es_organ s/covid -19_
en. The data shared will be anonymous and include the 
following ones:
(1) Gender, age range (30–39, 40–49 etc.), co-morbidi-
ties
(2) Transfusion time point (in days from disease onset)
(3) Number, volume and anti-body titre of transfused 
unit(s
(4) Therapies administered to the patient in parallel 
(other than supportive care)
Table 1 Schedule of the assessments for each patient during the study
a Hemoglobin, Hematocrit, Platelet count, White blood cells count, Neutrophil, Lymphocyte, PaO2, FiO2, Na, K, urea, creatinine, protein, bilirubin, ferritin, CRP, 
D-dimers, fibrinogen, LDH, TGO, TGP, CPK
b Creatinine, platelet count, bilirubin, CRP, WBC count, Ferritin, Lymphocyte count
Procedures Visits
Screening Inclusion Treatment phase Follow-up
Day 1 Day 7 Day 14 Day 21 Day 28 ICU Discharge Day 90 Day 365
Informed consent x





APACHE II score x
SOFA score x x x x x
WHO disease progression scale x x x
CRP x x x x x
Viral load (NP or tracheal PCR)
Clinical frailty scale x
Concomitant drugs against SARS‑CoV‑2 x x x x x x
Biological findings xa xb xb x b xb
24 h‑diuresis x x x x x
Serum sample for central analysis x x x x
Mechanical ventilation x x x x x
Renal replacement therapy x x x x x
Vasoactive drugs x x x x x
ECMO x x x x x
Nosocomial infections x x x x x
Iatrogenic events x x x x x
Adverse events & Serious adverse event x x x x x
ADL scale x x x
Anxiety‑depression scale x x
EQ‑5D‑5L scale x x x
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(5) Clinical symptoms and laboratory parameters—
according to the WHO Ordinal Scale for Clinical 
Improvement [7] at the following time points:
(a) Prior to transfusion
(b) 5 days after transfusion
(c) At discharge (if the patient survives)
(6) Any serious adverse reactions or events possibly 
linked to the transfusion
(7) Length of hospitalisation (if no death).
The de-identified raw data will be available on request 
to the corresponding author on request at benoit.mis-
set@chuliege.be for the purpose of meta-analyses.
Data management and monitoring
Measurements will be performed by the investigators 
and clinical research assistants during their stay in the 
hospital and during medical visits at each time of end-
points (days 7, 14, 28) in case of hospital discharge, and 
by phone for the day 90 and for day 365 endpoint. Vital 
status, dependence on the ventilator and clinical and 
biological data to calculate the SOFA score will be col-
lected from the patient’s record. Viral load, expressed as 
cycle threshold, will be assessed from tracheal aspirates 
or naso-pharyngeal swabs and real time polymerase 
chain reaction (RT-PCR) assessment by the usual tech-
nique of the routine laboratory. Adverse events possibly 
related to study intervention will be collected prospec-
tively, according to definitions of iatrogenic events, trans-
fusion-related events and nosocomial infections by the 
investigator and the clinical research assistant in charge 
of the study. Scales assessing functional state, psycho-
logical state and quality of life will be collected over the 
phone at the day 90 visit and the day 365 visit by a clinical 
research assistant dedicated to this task by the coordinat-
ing center. The adverse events will be collected and sever-
ity rating according to Belgian guidelines. Data will be 
collected from the patients’ records by a clinical research 
assistant and monitored by the clinical center of UCL 
team. It will be pseudo-anonymized in a secure database 
that was built at Saint-Luc Hospital in Brussels, Belgium, 
and maintained on a dedicated server. The study will be 
monitored by a DSMB that will include international 
members, including a statistician, who are not involved 
in this protocol and independent of the promotor and 
the funder. The DSMB will review the safety data at least 
every 6 months and at each interim analysis.
Adverse events
Patients will be continuously monitored for adverse 
events. Events related to plasma infusion will be reported 
to the local transfusion service, which in turn will notify 
them to the national system for surveillance for hemov-
igilance. The adverse events due to SOC will be notified 
in the electronic case record form (eCRF) and reported 
to the coordinating investigator and to the chair of the 
DSMB. More details on the protocol can be found in 
Additional file 1. This protocol complies with the SPIRIT 
requirements, and the corresponding check-list is pro-
vided in Additional file 2.
Statistical analysis
Sample size
The primary outcome of the trial is mortality at day 28. 
Based on prior reports from China, Italy and UK, and 
consistent with personal observations, we anticipate that 
the mortality at day 28 will be around 40%. The reduction 
that we anticipate is empiric and in accordance with the 
single trial published to date [8]. We consider that a one 
third relative reduction in 28-day mortality is realistic and 
clinically relevant. As this reduction might be greater, we 
plan to perform an interim analysis for ethical reasons. 
With a two-sided α-risk of 0.05 and a β-risk of 0.20, the 
minimal number of patients to include to reach signifi-
cance for a one third relative reduction in 28-day mor-
tality (an absolute reduction of 13.5% day-28 mortality 
in the intervention group assuming a day-28 mortality of 
40% in the control group) is 250 in the control group and 
250 in the active group (total number of patients = 500). 
This number allows for four interim analyses to be per-
formed in addition to the final analysis, respectively 
after assessment of 100, 200, 300, 400 and 500 patients. 
Considering that others trials in COVID-19 may result 
in modification in mortality and therefore in SOC, we 
anticipate that the number of patients that is necessary 
to address our hypothesis may vary, and will have to be 
adapted depending on the results of the interim analyses.
Statistical analysis plan
Results will be analysed in intention to treat and 
expressed as means and standard deviations (SD) for 
quantitative variables with a Normal distribution and as 
medians and 25th to 75th percentiles for skewed distrib-
uted quantitative variables. Qualitative variables will be 
expressed using counts and percentages.
Mean values between groups will be compared by Stu-
dent t-test but also by the non-parametric Wilcoxon test 
when normality assumption is not fulfilled. Proportions 
will be compared by the chi-square test. Appropriate 
multivariate analyses will be performed to assess the rela-
tionship between outcome and patients’ characteristics 
and clinical features.
For the primary endpoints, vital status at day 28 in all 
groups will be calculated with corresponding 95% CI. 
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Comparison between groups will be tested using chi-
square test.
Regarding the secondary endpoints, quantitative val-
ues between groups will be compared by Student t-test or 
non-parametric Wilcoxon for the sequential organ failure 
assessment (SOFA) score (at different time points), viral 
load of SARS-CoV-2 (at different time points), circulat-
ing C-reactive protein (CRP, at different time points), 
ADL score at day 90, anxiety-depression scale at day 
90, sero-conversion. Poisson regression analysis will be 
considered to analyse number of ventilator-free days up 
to day 28. Comparison of proportions will be applied to 
compare location of patient at day 90, as well as presence 
of various adverse events. If descriptive analysis revealed 
the presence of potential confounding factors, appropri-
ate multivariate analysis will then be considered.
The two-sided level of significance used in this trial is 
5%. Statistical analyses will be carried out using Statisti-
cal Analysis System (SAS, version 9.4 for Windows) sta-
tistical package.
Interim analysis plan
Due to ethical considerations of the current situation, 
we propose to conduct a group-sequential design with 
several interim analyses. The objective of including 
interim analyses in the study design is to allow the pos-
sibility of stopping the study early if a clinically relevant 
benefit is already established from a statistical point 
of view. Conversely, the interim analyses also allow 
the possibility of an early stopping of the study if the 
observed benefit, at the time of the interim analysis, is 
so small as to make it extremely unlikely that the study 
would succeed, were it continued until full accrual. 
Finally, the interim analyses will also include a futility 
stopping rule for the SOC group, which may appear 
to be unjustified if mortality in that group appears too 
large to be acceptable.
Specifically, the interim assessment of the SOC group 
will be based on the numbers of patients and of deaths 
shown in Table 2. The recommendation will be made to 
stop accruing patients in the SOC group if the number 
of deaths observed in this group suggests a true mor-
tality rate in excess of 0.4. The rule for DSMB recom-
mendation shown in Table 2 will not be binding. If the 
recommendation of the DSMB is to stop the trial, it will 
be provided to the Ethics Committee by the sponsor. 
The sponsor shall discontinue—temporarily or defi-
nitely—the trial by take into account the recommenda-
tions of the DSMB and the Ethics Committee.
The interim analyses will be performed with 100, 200, 
300 and 400 patients evaluable for 28-day mortality. 
Two Lan-Demets spending functions will be used: one, 
similar to a Pocock (aggressive) boundary to stop the 
study for futility, and the other, similar to an O’Brien-
Fleming (conservative) boundary to stop the study for 
extreme efficacy, If the interim analyses take place with 
increments of exactly 100 patients, and assuming a 
mortality of 40% in the control group, the recommen-
dations to stop the study for futility or for efficacy are 
summarized in Table 3. Of note, the trial will reach sta-
tistical significance if the absolute difference in 28-day 
mortality is 9% or larger, which might still be a clini-
cally worthwhile difference. The rules for DSMB rec-
ommendations shown in Table 3 will not be binding.
Table 2 interim analysis and  potential recommendation 















1 25  ≥ 14  < 0.034
2 50  ≥ 26  < 0.031
3 75  ≥ 37  < 0.04
4 100  ≥ 48  < 0.042
Table 3 interim analyses and potential recommendations of the DSMB to stop the trial for futility or efficacy, depending 
on the observed treatment effect (and associated P-value)
Interim analysis Number of patients Recommend stopping for futility if difference 
in mortality is smaller than
Recommend stopping for efficacy 
if difference in mortality is greater 
than
1 100 0.02 (P > 0.83) ‑
2 200 0.04 (P > 0.60) 0.22 (P < 0.001)
3 300 0.06 (P > 0.28) 0.14 (P < 0.007)
4 400 0.08 (P > 0.12) 0.11 (P < 0.022)
5 (final) 500 ‑ 0.09 (P < 0.042)
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Provision for adaptive design changes at the time 
of interim analyses
Because of the considerable uncertainties about the out-
comes that will be observed in the two arms of the trial, 
the DSMB will be allowed to recommend design changes 
based on the observed data at the times of the interim 
analyses. These changes may include an adaptation of the 
sample size or the patient selection. Any such changes are 
adaptive in nature and will be implemented using appro-
priate methods to control the impact of these changes on 
the operating characteristics of the trial (especially the 
probability of type I error).
Funding and data sharing with the funder
The trial is funded by the Belgian Health Care Knowledge 
Center, named KCE, a federal agency which develops the 
KCE Trials program, consisting in publicly funded, non-
commercial, practice-oriented clinical trials. These stud-
ies address questions that are generally not studied by 
industry, despite their high social importance. The Uni-
versity hospital of Liège owns the Study Data, but pro-
vides KCE with a royalty-free unrestricted license to use 
the Study Data for non-commercial public health related 
purposes.
Dissemination of results and publication policy
The results will be submitted for presentation to interna-
tional societies of critical care and/or infectious diseases 
and for publication to an international scientific medical 
journal. The authorship will include the members of the 
writing and/or steering committee, the investigators in 
the participating centres. The data will be provided to the 
authors of international collaborative meta-analyses on 
request.
Discussion
This study will be the first to assess the efficacy of plasma 
collected from convalescents of COVID-19 in the popu-
lation of mechanically ventilated patients. The high mor-
tality of this specific population increases the chance to 
observe a difference between the two groups. The pro-
spective and randomized design will allow to give a solid 
answer to the question. A stratification on the delay from 
mechanical ventilation and inclusion in the study will 
allow to determine the optimal time to use the conva-
lescent plasma. The participation of 16 centers of all Bel-
gium will insure the external validity of the results and the 
recruitment of the patients in an acceptable time period. 
Selecting convalescent plasmas with a high titer of neu-
tralizing antibodies against SARS-CoV-2 will guaranty 
an homogeneous treatment in the intervention group 
and prevent the occurrence of the antibody-dependent 
enhancement of the disease [15]. Lastly, planning itera-
tive interim analyses will allow to stop the trial early in 
case of an ethical issue induced by the observed results.
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org/10.1186/s1289 0‑020‑01361 ‑x.
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